Literature DB >> 3190734

Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.

M A Le Bot1, J M Bégué, D Kernaleguen, J Robert, D Ratanasavanh, J Airiau, C Riché, A Guillouzo.   

Abstract

Both cytotoxicity and metabolism of five anthracyclines, namely doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin, were investigated in primary cultures of both rat and human adult hepatocytes and, for comparison, in a rat liver epithelial cell line. Toxicity was assessed by morphological examination and measurement of lactate dehydrogenase leakage after 24 hr of treatment. The rank order of toxicity for both rat and human hepatocytes was esorubicin greater than doxorubicin = epirubicin greater than or equal to idarubicin greater than daunorubicin, and for rat epithelial cells: esorubicin greater than or equal to epirubicin greater than idarubicin = daunorubicin = doxorubicin. Human cells were around 2-fold less sensitive than rat hepatocytes to all anthracyclines. Anthracyclines and their metabolites were analyzed by HPLC. Differences in both the percentages and routes of metabolism were demonstrated between rat and human hepatocytes. The main metabolite was the 13-dihydro-derivative (-ol derivative) in both species from daunorubicin, idarubicin and esorubicin. Glucuronides of epirubicin and epirubicinol were found only in human hepatocytes. In addition, several unidentified metabolites were detected of esorubicin, idarubicin and daunorubicin in rat hepatocytes. In human hepatocytes, only one unknown metabolite from daunorubicin and doxorubicin was found to be formed by cells from a different donor. In spite of variations between individuals, human hepatocytes generally metabolized anthracyclines more actively than did rat hepatocytes. Rat liver epithelial cells were only able to convert daunorubicin and idarubicin, the two molecules which have the best affinity for the non-specific NADPH-dependent aldoketoreductase system. Three compounds (doxorubicin, epirubicin and esorubicin) were present in large amounts in the cells as the parent drug, another (idarubicin) as the 13-dihydro-derivative. This comparative study on cytotoxicity and metabolism of five anthracyclines in rat and human hepatocyte cultures emphasises species differences and the importance of this in vitro model system for further analysis of the metabolism and effect of anthracyclines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190734     DOI: 10.1016/0006-2952(88)90069-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

2.  Epidermal growth factor, DNA synthesis and human hepatocytes.

Authors:  A P Li; C A Myers; M A Roque; D L Kaminski
Journal:  In Vitro Cell Dev Biol       Date:  1991-11

3.  Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo.

Authors:  M J Gómez-Lechón; P López; T Donato; A Montoya; A Larrauri; P Giménez; R Trullenque; R Fabra; J V Castell
Journal:  In Vitro Cell Dev Biol       Date:  1990-01

4.  Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model.

Authors:  Michael C Cochran; John R Eisenbrey; Michael C Soulen; Susan M Schultz; Richard O Ouma; Sarah B White; Emma E Furth; Margaret A Wheatley
Journal:  Acad Radiol       Date:  2011-11       Impact factor: 3.173

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 6.  Liver cell models in in vitro toxicology.

Authors:  A Guillouzo
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

Review 7.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 8.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

9.  Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.

Authors:  M A Le Bot; D Kernaleguen; J Robert; M Berlion; C Riché
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.